

Peter G Rose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1295366/publications.pdf>

Version: 2024-02-01

163
papers

2,941
citations

172386

29
h-index

182361

51
g-index

239
all docs

239
docs citations

239
times ranked

3448
citing authors

#	ARTICLE	IF	CITATIONS
1	Giant Cell Tumor of Bone: Risk Factors for Recurrence. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 591-599.	0.7	301
2	Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. <i>Cancer</i> , 1989, 64, 1508-1513.	2.0	205
3	Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 2676-2676.	0.8	199
4	Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 2136-2142.	0.8	135
5	Do Surgical Margin and Local Recurrence Influence Survival in Soft Tissue Sarcomas?. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 3003-3011.	0.7	129
6	Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 1181-1187.	0.7	109
7	A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2011, 122, 111-115.	0.6	101
8	Phase II Study of Paclitaxel and Valspodar (PSC 833) in Refractory Ovarian Carcinoma: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 2975-2982.	0.8	96
9	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017, 147, 85-91.	0.6	74
10	Management Strategies for Recurrent Endometrial Cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 873-885.	1.1	73
11	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 459-467.	0.6	61
12	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , 2018, 150, 247-252.	0.6	56
13	Surgical Technique: Porous Tantalum Reconstruction for Destructive Nonprimary Periacetabular Tumors. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 594-601.	0.7	53
14	How Does the Level of Sacral Resection for Primary Malignant Bone Tumors Affect Physical and Mental Health, Pain, Mobility, Incontinence, and Sexual Function?. <i>Clinical Orthopaedics and Related Research</i> , 2016, 474, 687-696.	0.7	51
15	A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). <i>Gynecologic Oncology</i> , 2015, 136, 240-245.	0.6	49
16	The Value of Preoperative Biopsy in the Management of Solid Presacral Tumors. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 756-760.	0.7	46
17	Tantalum Acetabular Cups Provide Secure Fixation in THA after Pelvic Irradiation at Minimum 5-year Followup. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 3041-3047.	0.7	45
18	How Does the Level of Nerve Root Resection in En Bloc Sacrectomy Influence Patient-Reported Outcomes?. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 607-616.	0.7	44

#	ARTICLE	IF	CITATIONS
19	Extended Sacropelvic Resection For Locally Recurrent Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 47-55.	0.7	43
20	Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. <i>Anticancer Research</i> , 2016, 36, 6161-6164.	0.5	42
21	Surgical Management of 121 Benign Proximal Fibula Tumors. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 3056-3062.	0.7	41
22	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 140, 204-209.	0.6	40
23	Abraxane for the Treatment of Gynecologic Cancer Patients With Severe Hypersensitivity Reactions to Paclitaxel. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1281-1283.	1.2	39
24	Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor. <i>Journal of Bone and Joint Surgery - Series A</i> , 2017, 99, e69.	1.4	39
25	Acute Encephalopathy Due to Aluminum Toxicity Successfully Treated by Combined Intravenous Deferoxamine and Hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 296-300.	1.0	38
26	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 133, 245-254.	1.2	38
27	A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2005, 96, 296-300.	0.6	35
28	Sacral Tumor Resection. <i>Spine</i> , 2011, 36, 1570-1578.	1.0	33
29	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016, 143, 294-301.	0.6	31
30	Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: A multi-institution study. <i>Gynecologic Oncology</i> , 2015, 136, 235-239.	0.6	28
31	High TGF- β 2 signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. <i>Npj Precision Oncology</i> , 2021, 5, 101.	2.3	28
32	Chemoradiotherapy. <i>Drugs</i> , 2000, 60, 1239-1244.	4.9	27
33	Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 452-458.	1.2	27
34	Atypical Notochordal Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2017, 41, 39-48.	2.1	24
35	Comparison of Porous Tantalum Acetabular Implants and Harrington Reconstruction for Metastatic Disease of the Acetabulum. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 1239-1247.	1.4	24
36	Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer. <i>Journal of Ovarian Research</i> , 2019, 12, 112.	1.3	22

#	ARTICLE	IF	CITATIONS
37	A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. <i>Gynecologic Oncology</i> , 2020, 158, 794-802.	0.6	21
38	Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1048-1052.	1.2	20
39	Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. <i>Gynecologic Oncology</i> , 2015, 136, 529-533.	0.6	19
40	Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2014, 134, 510-515.	0.6	18
41	Outcome of Sacropectic Resection and Reconstruction Based on a Novel Classification System. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 1956-1965.	1.4	18
42	Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 161, 211-220.	0.6	18
43	Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 350.e1-350.e10.	0.7	15
44	Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity. <i>Annals of Translational Medicine</i> , 2020, 8, 905-905.	0.7	15
45	Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 699-705.	0.6	15
46	Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage MÄ¼llerian cancer. <i>Gynecologic Oncology</i> , 2015, 139, 407-412.	0.6	14
47	The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e19.	1.0	13
48	Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 162, 368-374.	0.6	13
49	Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: A phase I Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006, 102, 236-239.	0.6	12
50	Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 45-50.	0.6	12
51	Morbidity and Functional Status of Patients With Pelvic Neurogenic Tumors After Wide Excision. <i>Clinical Orthopaedics and Related Research</i> , 2010, 468, 2948-2953.	0.7	11
52	Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1126-1133.	1.2	11
53	Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 161, 389-395.	0.6	11
54	Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e38.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 731.e1-731.e9.	0.7	10
56	Primary Melanoma of the Lung. , 2006, , 293-297.		9
57	Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1603-1606.	1.2	9
58	Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100499.	0.3	9
59	Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. <i>Gynecologic Oncology</i> , 2021, 160, 405-412.	0.6	9
60	Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 161, 194-201.	0.6	8
61	Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors. <i>Journal of Ovarian Research</i> , 2021, 14, 55.	1.3	8
62	Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 645-651.	0.6	8
63	Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers. <i>Immunotherapy</i> , 2021, 13, 1179-1192.	1.0	8
64	Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2007, 104, 114-119.	0.6	7
65	Chordomas. , 2006, , 614-625.		6
66	Large (36 or 40-mm) Femoral Heads Decreased the Rate of Dislocation After Revision Total Hip Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, 2095.	1.4	6
67	Stage IIB-IVA Cancer of the Cervix. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 404-414.	1.0	5
68	Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 986-988.	0.7	5
69	Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 907-911.	1.2	5
70	Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin. <i>Anti-Cancer Drugs</i> , 2020, 31, 747-750.	0.7	5
71	Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 101844.	0.6	5
72	Exophytic Lumbar Vertebral Body Mass in an Adult with Back Pain. <i>American Journal of Neuroradiology</i> , 2020, 41, 1786-1790.	1.2	4

#	ARTICLE	IF	CITATIONS
73	What's New in Musculoskeletal Tumor Surgery. Journal of Bone and Joint Surgery - Series A, 2020, 102, 2111-2119.	1.4	4
74	Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. Gynecologic Oncology, 2020, 158, 309-315.	0.6	4
75	Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002622.	1.2	4
76	Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma. Gynecologic Oncology Reports, 2021, 37, 100840.	0.3	4
77	Phyllodes Tumor of the Breast. , 2006, , 209-217.		3
78	Uncommon Cancers of the Bladder. , 2006, , 18-26.		3
79	Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases. Gynecologic Oncology Reports, 2017, 22, 32-36.	0.3	3
80	What's New in Musculoskeletal Tumor Surgery. Journal of Bone and Joint Surgery - Series A, 2019, 101, 2159-2166.	1.4	3
81	What's New in Musculoskeletal Tumor Surgery. Journal of Bone and Joint Surgery - Series A, 2021, 103, 2251-2260.	1.4	3
82	Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer. Gynecologic Oncology, 2022, 165, 90-96.	0.6	3
83	Cancer of the Small Bowel. , 2006, , 391-400.		2
84	Atypical and Malignant Meningiomas. , 2006, , 639-648.		2
85	Primary Lymphomas of the Lung. , 2006, , 257-263.		2
86	Adenoid Cystic Carcinoma of the Breast. , 2006, , 187-193.		2
87	Primary Sarcomas of the Lung. , 2006, , 264-278.		2
88	Small Cell Carcinomas of the Gastrointestinal Tract. , 2006, , 430-435.		2
89	Seromuscular Colonic Flap for Intrapelvic Soft-Tissue Coverage: A Reconstructive Option for Plastic Surgeons When Traditionally Used Flaps Are Not Available. Case Reports in Surgery, 2015, 2015, 1-3.	0.2	2
90	Landmark studies of therapeutic vaccination in cervical and ovarian cancers. Lancet Oncology, The, 2020, 21, 1549-1550.	5.1	2

#	ARTICLE	IF	CITATIONS
91	Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100876.	0.3	2
92	Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100951.	0.3	2
93	Uncommon Pediatric Brain Tumors. , 2006, , 798-809.		1
94	Urethral Cancer. , 2006, , 27-37.		1
95	Male Breast Cancer. , 2006, , 201-208.		1
96	Carcinoid Tumors of the Lung. , 2006, , 307-312.		1
97	Carcinosarcoma of the Breast. , 2006, , 218-229.		1
98	Uncommon Cancers of the Thyroid. , 2006, , 165-173.		1
99	Uncommon Cancers of the Esophagus. , 2006, , 337-351.		1
100	Tubular Carcinoma. , 2006, , 230-235.		1
101	Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797.		1
102	Gestational Trophoblastic Diseases. , 2006, , 532-542.		1
103	Uncommon Cancers of the Stomach. , 2006, , 352-366.		1
104	Langerhans' Cell Histiocytosis of the Central Nervous System. , 2006, , 610-613.		1
105	Metaplastic Breast Carcinoma. , 2006, , 181-186.		1
106	Meningeal Sarcomas. , 2006, , 626-637.		1
107	Large Cell Neuroendocrine Carcinoma. , 2006, , 298-306.		1
108	Rare Tumors of the Testis and Paratesticular Tissues. , 2006, , 66-85.		1

#	ARTICLE	IF	CITATIONS
109	Fallopian Tube Cancer. , 2006, , 477-484.		1
110	Rare Tumors of the Larynx. , 2006, , 102-112.		1
111	Primary Intracranial Germ Cell Tumors. , 2006, , 649-656.		1
112	Combination of a fillet flap, free tissue transfer, and autologous tissue grafts in pelvic reconstruction following retroperitoneal sarcoma: A case report. Microsurgery, 2015, 35, 320-323.	0.6	1
113	Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing. Anti-Cancer Drugs, 2019, 30, 636-639.	0.7	1
114	Team Approach: Oncologic Sacrectomy. JBJS Reviews, 2020, 8, e19.00226-e19.00226.	0.8	1
115	Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy. Journal of Surgical Oncology, 2021, 123, 1292-1298.	0.8	1
116	Posterior-First Two-Stage Approach to En Bloc Resection of Locally Recurrent Rectal Cancer Involving the Pelvic Sidewall. Diseases of the Colon and Rectum, 2021, 64, e465-e470.	0.7	1
117	Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study. Frontiers in Oncology, 2021, 11, 652683.	1.3	1
118	Rare Lymphomas. , 0, , 555-568.		1
119	Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology, 2022, , .	0.7	1
120	Esthesioneuroblastoma. , 2006, , 133-142.		0
121	Uncommon Cancers of the Prostate. , 2006, , 38-65.		0
122	Unusual Tumors of the Colon, Rectum and Anus. , 2006, , 401-409.		0
123	Tumors of the Vulva and Vagina. , 2006, , 521-531.		0
124	Tumors of the Cervix. , 2006, , 501-520.		0
125	Primary Central Nervous System Lymphoma. , 2006, , 657-666.		0
126	Mesotheliomas. , 2006, , 279-292.		0

#	ARTICLE	IF	CITATIONS
127	Bronchioloalveolar Carcinoma of the Lung. , 2006, , 313-320.		0
128	Borderline Tumors and Other Rare Epithelial Tumors of the Ovary. , 2006, , 447-454.		0
129	Germ Cell Tumors of the Ovary. , 2006, , 467-476.		0
130	Mucoepidermoid Tumors of the Lung. , 2006, , 329-335.		0
131	Uterine Sarcomas and Unusual Endometrial Carcinomas. , 2006, , 485-500.		0
132	Uncommon Tumors of the Oral Cavity and Adjacent Structures. , 2006, , 87-101.		0
133	Uncommon Tumors of the Gastrointestinal Tract in Children. , 2006, , 749-759.		0
134	Uncommon Pediatric Genitourinary Tumors. , 2006, , 760-774.		0
135	Nasopharyngeal Carcinoma in Non-endemic Populations. , 2006, , 113-132.		0
136	Stromal Tumors of the Ovary. , 2006, , 455-466.		0
137	Malignant Tumors of the Skin and Subcutaneous Tissue in Children. , 2006, , 810-818.		0
138	Thymoma and Thymic Carcinoma. , 2006, , 237-256.		0
139	Glioma and Other Neuroepithelial Neoplasms. , 2006, , 674-694.		0
140	Uncommon Tumors of the Kidney. , 2006, , 1-17.		0
141	Extra-ovarian Primary Peritoneal Carcinomas. , 2006, , 437-446.		0
142	Choroid Plexus Papilloma and Carcinoma. , 2006, , 667-673.		0
143	Neoplastic Disorders of the Adrenal Glands. , 2006, , 143-164.		0
144	Uncommon Pediatric Tumors of the Thorax. , 2006, , 732-748.		0

#	ARTICLE	IF	CITATIONS
145	Craniopharyngiomas. , 2006, , 705-711.		0
146	Primary Adenoid Cystic Carcinoma of the Lung. , 2006, , 321-328.		0
147	Unusual Cutaneous Malignancies. , 2006, , 577-588.		0
148	Melanotic Lesions of the Meninges. , 2006, , 605-609.		0
149	Ophthalmic Cancers. , 2006, , 712-720.		0
150	Non-Hodgkin Lymphoma of the Breast. , 2006, , 194-200.		0
151	Unusual Pancreatic Tumors. , 2006, , 367-382.		0
152	Cancer of the Appendix. , 2006, , 410-417.		0
153	Gastrointestinal Stromal Tumors. , 2006, , 418-429.		0
154	Rare Leukemias. , 2006, , 543-554.		0
155	Uncommon Hepatobiliary Tumors. , 2006, , 383-390.		0
156	Medulloblastoma and CNS Primitive Neuroectodermal Tumors. , 2006, , 695-704.		0
157	Distal Femoral Subchondral Metastasis Mistaken for an Insufficiency Fracture and Treated with Total Knee Arthroplasty. JBJS Case Connector, 2014, 4, e91.	0.1	0
158	Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma. Gynecologic Oncology, 2021, 163, 511-516.	0.6	0
159	Uncommon Presentations of Plasma Cell Dyscrasias. , 0, , 569-575.		0
160	Rare Pediatric Malignancies of the Head and Neck. , 0, , 721-731.		0
161	Life or limb: an international qualitative study on decision making in sarcoma surgery during the COVID-19 pandemic. BMJ Open, 2021, 11, e047175.	0.8	0
162	To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?. Gynecology & Obstetrics (Sunnyvale, Calif), 2021, 11, .	0.1	0

#	ARTICLE	IF	CITATIONS
163	The Overtreatment and Cost Effectiveness of Primary Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).. Gynecology & Obstetrics (Sunnyvale, Calif), 2021, 11, .	0.1	0